Fibroblast activating
protein DPP-IV
Stroma tissue supporting the cancer cells
Cancer cell growth
DPP-IV (CD26) inhibitor*

Immuno effector cell
IL1b
Monocyte
DPP-IV
-
-
-
-
-
-
Two key factors of tumor control are DPPs (dipeptidyl peptidases) :
- Fibroblast activating protein, secreted by the stromal cells supporting the cancer tissue, which enhances tumor growth
- An inhibitor of IL1b release,  decreasing immune defense
HealthValue
Back to home page
CANCER : the DPP-IV pathway
* Talabostat is a DPP-IV inhibitor in advanced clinical trials for cancer
MONOCLONALS
abatacept
abciximab
adalimumab
alefacept
alemtuzumab
anti KDR
basiliximab
belatacept
bevacizumab
CDP 791
cetuximab
dacluzimab
denosumab
eculizumab
efalizumab
etanercept
IMC 1121
infliximab
ipilimumab
lumiliximab
Mab 806
mapatumumab
matuzumab
natalizumab
nimotuzumab
ocrelizumab
ofatumumab
omalizumab
palivizumab
panitumumab
ranibizumab
rituximab
ticilimumab
trastuzumab
VEGF Trap
zalutumumab
ABOUT MONOCLONALS
what is a monoclonal
chains & fragments
therapeutic fields
what are CDs
types of monoclonals
fusion proteins
cells to build monoclonals
making monoclonals
IgG1/IgG2 differences
F(ab) fragments
Fc fragment
Fc structure
Fc e receptors
DISEASES
bird flu
cancer
diabetes
human growth hormone diseases
lysosomal diseases
mitochondrial diseases
multiple sclerosis
myelodysplastic sd
myopathies
osteoporosis
paroxysmal nocturnal hemoglobinuria
psoriasis
BioTherapies
antisense
cell therapy
exon skipping
gene therapy
hemopoietic prog.
monoclonals
protein kinases
recombinant prot.
stem cells
Cells/organelles
cell cycle
cells
chromosomes
DNA repair
exons
hemopoietic prog.
introns
lysosomes
mb. receptors
membrane CDs
mitochondria
proteasomes
stem cells
Pathways
Adams
AKT
amino acids
complement
cancer pathways
cdk
DPP IV
EGF
EGFRvIII
GPCR
G proteins
ILGF
kinome
Kras
mannose P
NFKB
nucleotides
protein kinases
proteins
Ras
RET
sheddases
sunitinib/sorafenib
VEGF
Wnt